Search Results
Results found for "Brigitte Kieffer"
- AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof
AlphaFold-predicted models revealed distinct ligand-binding site shapes, enabling the prioritization of different static structures was groundbreaking, however, GPCRs are highly dynamic proteins and continuously adopt different ligands and the cellular environment which are crucial for understanding how drugs can selectively target different
- Molecular basis for ligand modulation of the cannabinoid CB 1 receptor
New high-resolution structures of CB1 receptor in different functional states have significantly improved These advances have paved the way for development of novel ligands for different therapeutic applications In this review, we describe the structural determinants for modulation of CB1 receptors by different types of ligands, as well as the differences between CB1 and its homologous, the CB2 receptor.
- How to Avoid the Most Common Gaps in Your Biotech Pitch
If your pitch doesn’t immediately tell them who it’s for, why it matters, and what makes it different immediately shifts the conversation from academic interest to practical significance. 3️⃣ Why it’s different understand what sets your approach apart from existing solutions or current standards and why that difference What Changes When Your Pitch Works When your biotech pitch lands, the difference is immediate and powerful
- Why “Displacement” Misleads You: Allosteric Binding Demystified
allosteric systems , adding a modulator doesn’t push another molecule off—it transforms the receptor into a different Function: Two Different Worlds One of the most common—and dangerous—mistakes in allosteric pharmacology Allosteric Binding Is a Different Game. Learn the Rules.
- Differential binding of Δ9-tetrahydrocannabinol derivatives to type 1 cannabinoid receptors (CB1)
It has been proven that when different ligands bind to the receptors the effects are different depending Raïch I et al. , Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinolderivatives
- Radioligands vs. Fluorescent Ligands: Binding Assays
Fluorescent Probes: Differences in Binding Assays Fluorescent ligands are a type of fluorescent probes ligands can be used at a broader range of concentration without losing accuracy, as well as detect different Ease of handling is the other key difference, because fluorescent compounds do not require regulatory
- β-arrestin1 and 2 exhibit distinct phosphorylation-dependent conformations when coupling to the...
when coupling to the same GPCR in living cells "β-arrestins mediate regulatory processes for over 800 different However, whether β-arrestin1 and 2 respond differently for binding to the same GPCR is still unknown. that the two isoforms prefer to associate with the active parathyroid hormone 1 receptor (PTH1R) in different Here, we show differences between conformational changes that are induced by P-R* or R* receptor states
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Terry Kenakin reframes one of pharmacology’s most foundational ideas: the difference between competitive This lecture helps you not only understand these differences, but also know when and why they matter. This is the kind of insight that makes the difference between a dead-end program and a well-informed
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
This lecture is a roadmap for understanding why two drugs with similar affinity may behave completely differently Cryptic Sites, Longer Onset: Why Some Drugs Work Differently in Cells Than in Assays One of the most What If the Same Site Behaves Differently Depending on the Ligand?
- How System-Level GPCR Thinking Prevents Discovery Failures
Most GPCR programs don’t fail because of weak molecules—they fail because biology behaves differently When you see the distortions baked into the system, you interpret your data differently and protect your What You’ll Gain Spot false confidence early → Sensitivity differences can turn full agonists into partials
- TM5-TM6: structural switches that modulate the coupling of serotonin receptors to Gs or Gi
What is the molecular basis that determines that GPCRs bind selectively or promiscuously to different Prior to this report we did not know how different serotonin receptor subtypes which share high sequence homology, coupled to different families of G proteins, so the comparison and structural analysis of The structural differences found between the receptor-Gs and receptor-Gi complexes evidenced that 5-HT4 These differences are mainly attributed to the characteristic Ras domain distance between Gs and Gi.
- VAMP2: a crucial player in the delivery of MOR to the synapse
The t-SNARE complex is composed of two different proteins: syntaxin and SNAP-25; syntaxin is found on However, the selectivity of SNARE complex proteins to regulate the release of different types of GPCRs its bi-leucine sequence (which is considered a key element in its recycling), which can interact with different fusion proteins and also this different molecular codes will be modulated by different opioids, either endogenous or exogenous, promoving a differential organization of MOR receptors in vesicles with different
- The Hidden Burn: How Internal Misalignment Drains Your Biotech’s Runway
At first, it’s just different vocabulary. Later, it becomes different roadmaps. In reality, they’re solving different problems. You pay for both. You benefit from neither. They suffer because everyone has a different idea of what their role actually is.
- Tracking receptor motions at the plasma membrane reveals distinct effects of ligands on CCR5...
August 2022 "G-protein-coupled receptors (GPCR) are present at the cell surface in different conformational We used TIRF microscopy and a statistical method to track and classify the motion of different receptor These forms were stabilized differently by distinct ligands.
- Ever Wondered How Drugs Are Discovered?
You’ll explore: What makes a “discovery team” tick (and why teamwork is non-negotiable) The difference
- Comparative study of neuropeptide signaling systems in Hemiptera
signaling system, there is still a great deal of variety in neuropeptides and their receptors among different Neuropeptides and their receptors have been documented in many hemipteran insects, but the differences Additionally, we discovered that the neuropeptide signaling systems of Sternorrhyncha were very different
- The NPXXY Motif Regulates β-Arrestin Recruitment by the CB1 Cannabinoid Receptor
2022 "Background: Activation of signaling effectors by G-protein coupled receptors (GPCRs) depends on different indicated that transmembrane helix 7 (TMH7) and the highly conserved NPXXY motif can be subject to different
- Knowing When to Walk, Knowing When to Run: Lessons from the Bench
Knowing the difference is survival.
- From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations
Startups Play by Different Rules — and Most Scientific Founders Miss That A research lab is designed And that difference changes everything. 👉 Scientific thinking values thoroughness, error reduction, Startups demand something different: ✅ Clarity of direction even when the picture is incomplete.
- Structural basis of GPCR coupling to distinct signal transducers: implications for biased signaling
no generalizable GPCR conformations conducive to binding a particular type of partner; (ii) subtle differences receptor-transducer structures determine partner preference; or (iii) the dynamics of GPCR binding to different
- How a Failed Experiment Created a Powerful GPCR Imaging Tool
Instead of abandoning the compound, the team did something different: they looked at what it could do It happened because Hodson and JB thought differently — and allowed the clash of disciplines to be productive
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
The difference between orthosteric vs. allosteric mechanisms isn’t just academic — an orthosteric antagonist Allosteric sites operate differently: ligands bind elsewhere, transmit energy changes, and shift the That perspective helps explain why two compounds with similar affinities can deliver very different clinical
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
One of the biggest hurdles is the understanding and correct targeting of the different receptor subtypes Depending on the type of GPCR, it can lead to different secondary messengers , like cAMP, IP3, which Some agonists induce conformations more adept at activating β-arrestins for example, leading to different
- Beyond the Probe: Scaling Innovation From the Bench to Product Launch
Their method allows researchers to explore different linker positions, tailor activity (agonist or antagonist
- Isoforms of GPR35 have distinct extracellular N-termini that allosterically modify...
GPR35 is known to be expressed as two distinct isoforms that differ only in the length of their extracellular N-termini by 31 amino acids, but detailed insights into their functional differences are lacking. thoroughly profile both GPR35 isoforms for constitutive and ligand-induced activation and signaling of 10 different
- Chemerin Forms: Their Generation and Activity
discusses the specific tissue expression of the components of the chemerin system, and the role of different Methods of identifying and determining the levels of different chemerin forms in both mass and activity
- AlphaFold2 versus experimental structures: evaluation on G protein-coupled receptors
However, the predicted models and experimental structures were different in many aspects including the These differences impeded the use of predicted structure models in the functional study and structure-based
- GPCR Collaboration: From Models to Medicine
GPCRs demanded something different: the integration of modeling, medicinal chemistry, and pharmacology ligands, he relies on a network of collaborators worldwide , each bringing specialized expertise in different If docking can suggest binding modes but can’t resolve nanomolar potency differences, they say so.
- 📰 GPCR Weekly News, April 29 to May 5, 2024
We got a little busy with all the major events at Dr.GPCR, so our weekly news looks slightly different
- Disentangling bias between G q, GRK2, and arrestin3 recruitment to the M 3 muscarinic acetylcholine
Different agonists can promote differential receptor-induced signaling responses - termed bias - potentially by eliciting different levels of recruitment of effector proteins. inhibitors of Gi and Gq proteins and analyzed arrestin3 binding to prestimulated M3 receptors to avoid differences We measured substantial differences in the agonist efficacies to induce M3R-arrestin3 versus M3R-GRK2
















